SSR69071

SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury[1]. SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases[2].

Product Specifications

CAS Number

[344930-95-6]

UNSPSC

12352005

Target

Elastase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ssr69071.html

Purity

98.4

Solubility

DMSO : 52 mg/mL (ultrasonic; warming)

Smiles

O=C1C=C(OCN(C(C2=C3C=C(OC)C=C2C(C)C)=O)S3(=O)=O)N=C4N1C=CC=C4OCCN5CCCCC5

Molecular Formula

C27H32N4O7S

Molecular Weight

556.63

References & Citations

[1]Jean-Pierre Bidouard, et al. SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur J Pharmacol. 2003 Feb 7;461 (1) :49-52.|[2]Zoltan Kapui, et al. Biochemical and pharmacological characterization of 2- (9- (2-piperidinoethoxy) -4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl) -4- (1-methylethyl) -6-methoxy-1,2-benzisothiazol-3 (2H) -one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J Pharmacol Exp Ther. 2003 May;305 (2) :451-9.|[3]Márton Varga, et al. A novel orally active inhibitor of HLE. Eur J Med Chem. 2003 Apr;38 (4) :421-5.